Abstract
Basal cell carcinoma (BCC) is the most common cutaneous malignancy. Although indolent, BCCs can be locally aggressive if untreated. Dysregulated hedgehog (Hh) signaling leads to uncon-trolled proliferation in BCC. Vismodegib is a small-molecule antago-nist of the Hh pathway that binds to smoothened (SMO), a transmembrane protein, and causes inhibition of an aberrant activa-tion of the Hh pathway. Vismodegib is the first drug approved by the US Food and Drug Administration (FDA) for the management of locally advanced or metastatic BCC.Cutis. 2022;110:155-158.